A Randomized Study of Sulindac in Oral Premalignant Lesions

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 23, 2006

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Leukoplakia, OralBenign Neoplasms
Interventions
DRUG

sulindac

Sulindac 150 mg po bid x 24 weeks

DRUG

Placebo

Placebo bid x 24 weeks

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

Unknown

Amrita Institute of Sciences (AIMS), Kochi

Regional Cancer Center (RCC), Trivandrum

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AIMS Institute

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Regional Cancer Centre, Trivandrum, India

OTHER

collaborator

Narayana Hrudayalaya Hospitals

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER